Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

Psoriasis Clinical Trial

— DCE  

Official title:

Patient Preference for Treatment of Moderate-To-Severe Psoriasis in Japan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05065762
• Other study ID #: IM011-174
• Status: Completed
• Start date: October 1, 2021
• Est. completion date: February 7, 2022

Study information

• Verified date: May 2022
• Source: Bristol-Myers Squibb
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 232
• Est. completion date: February 7, 2022
• Est. primary completion date: February 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)

• Currently taking systemic psoriasis treatment

• Japanese resident aged 20 years and older

Exclusion Criteria:

• Unable or unwilling to provide informed consent

• Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Related Conditions & MeSH terms

• Psoriasis

Locations

Country	Name	City	State
United States	Local Institution	Morrisville	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute		Within 60 minutes of survey/interview
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex		At Baseline
Primary	Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age		At Baseline
Primary	Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis		At Baseline
Primary	Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO		At Baseline
Primary	Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO		At Baseline
Primary	Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment		At Baseline
Primary	Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence		At Baseline
Primary	Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status		At Baseline
Primary	Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education		At Baseline
Primary	Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments		At Baseline
Primary	Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO		At Baseline
Primary	Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education		At Baseline
Primary	Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis		At Baseline
Primary	Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity		At Baseline
Primary	Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO		At Baseline
Primary	Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment		At Baseline
Primary	Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO		At Baseline
Primary	Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest		At Baseline
Primary	Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income		At Baseline

External Links

•   BMS Clinical Trial Information
•   FDA Safety Alerts and Recalls